Pharmaceutical compositions for the treatment of acute myeloid leukemia comprising an FLT3 inhibitor and a hypomethylating agent - Patent Application 20070229333

Combining a FLT3 inhibitor with a hypomethylating agent enhances treatment efficacy against AML by addressing drug resistance and targeting stem/progenitor cells, improving survival and reducing recurrence.

JP7577672B2Active Publication Date: 2024-11-05HANMI PHARM CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021547541
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-02-21
Filing Date
2020-02-21
Publication Date
2024-11-05
Estimated Expiration
2040-02-21

AI Technical Summary

Technical Problem

Current treatments for acute myeloid leukemia (AML), particularly those targeting FLT3 mutations, face challenges with drug resistance and inability to effectively target stem/progenitor cells, leading to recurrence and limited long-term efficacy.

Method used

A combination therapy using an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a hypomethylating agent (HMA) is administered either simultaneously, sequentially, or separately to enhance therapeutic efficacy against AML, including mutations in FLT3.

Benefits of technology

The combination therapy significantly increases therapeutic efficacy against AML by overcoming drug resistance and targeting stem/progenitor cells, leading to improved survival rates and reduced recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577672000014
    Figure 0007577672000014
  • Figure 0007577672000015
    Figure 0007577672000015
  • Figure 0007577672000016
    Figure 0007577672000016
Patent Text Reader

Abstract

Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), which comprises a therapeutically effective combination of an Fms-like tyrosine kinase (FLT3) inhibitor, a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA), a pharmaceutically acceptable salt or solvate thereof, and a method for treating acute myeloid leukemia (AML) using the same.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for treating acute myeloid leukemia, comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor and a hypomethylating agent (HMA), and a method for treating acute myeloid leukemia using the same. [Background technology]

[0002] Fms-like tyrosine kinase-3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia (AML). Mutant FLT3 refers to a mutation expressed in leukemic cells that is present in a subpopulation of acute myeloid leukemia (AML) patients. Activating mutations in FLT3, such as internal tandem duplications (ITDs) in the membrane juxtamembrane domain, are present in approximately 25-30% of newly diagnosed acute myeloid leukemia (AML) cases (Patent Document 1). It is known that FLT3 mutations occur in approximately one-third of acute myeloid leukemia (AML) patients (Non-Patent Document 1).

[0003] There are several FLT3 inhibitors available for clinical use, but in acute myeloid leukemia (AML) patients treated with such FLT3 inhibitors, drug-resistant white blood cells were observed, indicating drug resistance (Non-Patent Document 1). In addition, the conventional standard chemotherapy for acute myeloid leukemia (AML) has the problem that it is impossible to target acute myeloid leukemia (AML) stem / progenitor cells, and patients frequently relapse, thereby limiting long-term efficacy (Non-Patent Document 2). Therefore, a method that can effectively treat patients with mutant acute leukemia is needed.

[0004] In an attempt to solve the resistance to FLT3 inhibitors, the administration of FLT3 inhibitors in combination with inhibitors of PI3K / Akt, MAPK and JAK / STAT signaling pathways has been studied (Non-Patent Document 3). Inhibitors of apoptosis protein (IAP) inhibitors refer to proteins that play a role in mediating apoptosis, and these proteins are known to be expressed in various ways in acute leukemia and to be involved in chemosensitivity, chemosensitivity, disease progression, remission and patient survival (Non-Patent Document 3). A treatment method for acute myeloid leukemia (AML) and hematological malignancies combining such inhibitors of apoptosis protein (IAP) inhibitors and FLT3 inhibitors has been studied (Patent Document 2).

[0005] A hypomethylating agent (demethylating agent or hypomethylating agent) refers to an agent that hypomethylates DNA, and includes azacitidine, decitabine, idarubicin, etc. For example, decitabine is used clinically for primary and secondary myelodysplastic syndromes (MDS). Azacitidine is a drug with the chemical name "4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one" and is commercially available under the brand name Vidaza. Azacitidine is known as a nucleoside metabolic inhibitor (hypomethylating agent) for the treatment of patients with FAB myelodysplastic syndrome (MDS) subtype. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Korean Patent Publication No. 10-2018-0124055 [Patent Document 2] Korean Patent Publication No. 10-2009-0087094 [Non-patent literature]

[0007] [Non-Patent Document 1] Mol Cancer Ther 2007; 6(7), July 2007 [Non-Patent Document 2] J Natl Cancer Inst. Vol. 106, Issue 2, djt440, February 5,2014 [Non-Patent Document 3] Oncogene. 2010 Sep 16; 29(37): 5120-34 Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention provides an alternative therapy for the treatment of acute myeloid leukemia (AML), including patients with FLT3 mutations, which may lead to better therapeutic outcomes. [Means for solving the problem]

[0009] FLT3 (Fms-like tyrosine kinase-3) is a promising therapeutic target for leukemia and is mutated in approximately 30% or more of patients with acute myeloid leukemia (AML). However, there is growing concern about the development of drug resistance and refractoriness due to the emergence of point mutations in targeted tyrosine kinases used to treat acute leukemia patients. One approach to overcome such resistance is to combine structurally unrelated inhibitors and / or inhibitors of different signaling pathways to determine whether efficacy and therapeutic effect are enhanced.

[0010] One aspect of the present invention provides a pharmaceutical composition for treating acute myeloid leukemia (AML), comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor, a pharma- ceutical acceptable salt thereof, or a solvate thereof, and co-administered with a hypomethylating agent (HMA), a pharma- ceutical acceptable salt thereof, or a solvate thereof, wherein the FLT3 inhibitor is a compound selected from the group consisting of a compound of Formula 1, a stereoisomer thereof, a tautomer thereof, and a combination thereof.

[0011] Another aspect of the present invention provides a pharmaceutical kit, wherein the pharmaceutical compositions are administered simultaneously, sequentially, in reverse order or separately.

[0012] Another aspect of the present invention provides a pharmaceutical composition for treating acute myeloid leukemia (AML), comprising a hypomethylating agent (HMA), or a pharma- ceutical acceptable salt or solvate thereof, in combination with an Fms-like tyrosine kinase (FLT3) inhibitor, or a pharma- ceutical acceptable salt or solvate thereof. Effect of the Invention

[0013] One aspect of the present invention provides a pharmaceutical composition of an Fms-like tyrosine kinase (FLT3) inhibitor and a hypomethylating agent (HMA), and a kit or combination comprising said composition.

[0014] One aspect of the present invention provides a method for treating hematological malignancies including acute myeloid leukemia (AML) using the pharmaceutical composition, kit or combination, and use of the composition for treating acute myeloid leukemia.

[0015] In one aspect of the present invention, the pharmaceutical composition, kit or combination can be provided to enhance the therapeutic effect of acute myeloid leukemia (AML), including patients with FLT3 mutation. [Brief description of the drawings]

[0016] [Figure 1] This shows the degree of inhibition of MOLM-13 cell growth by combined treatment with Compound A and azacytidine. The Y axis shows cell growth rate (%), and the X axis shows the logarithmic concentration of Compound A (log value of concentration in nM units). [Diagram 2] The degree of cell growth inhibition was confirmed when Compound A 2.5 nM, Azacitidine 800 nM, or a combination of Compound A 2.5 nM and Azacitidine 800 nM was used. The Y axis indicates the cell growth rate (%), and the X axis indicates each experimental group. [Diagram 3] This shows the antitumor effect of administering a combination of Compound A and azacytidine to nude mice xenografted with MOLM-13-Luc2 cell line. The Y-axis shows the percentage of surviving mice (survival rate) (%) in each experimental group, and the X-axis shows the number of days of administration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the art in the field of the present invention unless otherwise defined. In addition, although preferred methods and samples are described in this specification, similar or equivalent methods and samples are also included in the scope of the present invention. In addition, numerical values ​​described in this specification are considered to include the meaning of "about" even if not expressly stated. The contents of all publications described as references in this specification are incorporated herein by reference in their entirety.

[0018] One aspect of the present invention provides methods, uses, combinations, kits, and compositions for the treatment of acute myeloid leukemia (AML), comprising an Fms-like tyrosine kinase-3 (FLT3) inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof, as a combination effective for the treatment of acute myeloid leukemia (AML).

[0019] As used herein, acute myeloid leukemia (AML) includes acute myeloid leukemia with FLT3 mutation.In one embodiment, acute myeloid leukemia (AML) includes mutant FLT3 polynucleotide positive acute myeloid leukemia (AML), FLT3 internal tandem duplication (ITD) positive acute myeloid leukemia (AML) or acute myeloid leukemia (AML) with FLT3 point mutation.

[0020] FLT3 is a member of the class III receptor tyrosine kinase (TK) family that is normally expressed on the surface of hematopoietic stem cells. FLT3 and its ligands play important roles in the proliferation, survival, and differentiation of pluripotent stem cells. FLT3 is expressed in many acute myeloid leukemia (AML) cases. Activated FLT3 with internal tandem duplications (ITDs) in and around the membrane juxtamembrane domain and tyrosine kinase domain (TKD) mutations near D835 in the activation loop are present in 28% to 34% and 11% to 14% of acute myeloid leukemia (AML) cases, respectively. These activating mutations in FLT3 are tumorigenic and exhibit transforming activity in cells. Patients with FLT3-ITD mutations have a poorer prognosis in clinical studies, with a higher relapse rate, shorter duration of remission from initial treatment (6 months compared to 11.5 months in patients without FLT3-ITD mutations), reduced disease-free survival (16% to 27% at 5 years compared to 41%), and reduced overall survival (OS) (15% to 31% at 5 years compared to 42%). The occurrence of relapse after hematopoietic stem cell transplantation (HSCT) has also been associated with a higher incidence of FLT3- It is even higher in patients with ITD (30% at 2 years compared with 16% in patients without FLT3-ITD mutations). Similar to the prognosis following first-line treatment, patients with relapsed / refractory FLT3-mutation-positive acute myeloid leukemia (AML) have lower remission rates with salvage anticancer therapy, shorter time to remission until second relapse, and reduced OS compared with FLT3-mutation-negative patients.

[0021] In this specification, the FLT3 inhibitor is 4'-N-benzoylstaurosporine (ingredient name: midostaurin), 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2H-pyran-4-yl)amino]-2-pyrazinecarboxamide (ingredient name: gilteritinib ), 1-(2-{5-[(3-methyloxetan-3-l)methoxy]-1H-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine (ingredient name: crenolanib), 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea (ingredient name: Quizartinib), 2-hydroxy-1-(2-((9-((1r,4r)-4-methylcyclohexyl)-9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone (FLX925), (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propyl and substances such as 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one (TAK-659).

[0022] Compounds having kinase inhibitory activity described in International Patent Application Publication No. WO2018-139903, or compounds having FLT3 inhibitory activity described in Korean Patent Application No. 10-2018-0086768, or any pharma- ceutically acceptable salt or hydrate form of an FLT3 inhibitor thereof, but are not limited to these substances.

[0023] In one embodiment, the FLT3 inhibitor is a compound having kinase inhibitory activity described in International Patent Application Publication No. WO2018-139903, or a compound having FLT3 inhibitory activity described in Korean Patent Application No. 10-2018-0086768, or any pharma- ceutically acceptable salt or hydrate thereof.

[0024] One aspect of the present invention provides a pharmaceutical composition for treating acute myeloid leukemia (AML), comprising an Fms-like tyrosine kinase (FLT3) inhibitor, a pharma- ceutical acceptable salt thereof, or a solvate thereof, which is administered in combination with a hypomethylating agent (HMA), a pharma- ceutical acceptable salt thereof, or a solvate thereof, wherein the FLT3 inhibitor is a compound selected from the group consisting of a compound of Formula 1, a stereoisomer thereof, a tautomer thereof, and combinations thereof.

[0025] [ka]

[0026] In the above Chemical Formula 1,

[0027] E a is hydrogen, hydroxy or C1-C4 alkoxy;

[0028] E b is hydrogen, halogen, C1-C4 alkyl or C1-C4 fluoroalkyl;

[0029] E c and E d are, independently of each other, hydrogen or hydroxy,

[0030] X' is hydrogen or hydroxy;

[0031] k is an integer of 1 or 2,

[0032] each Q is independently hydroxy, halogen, C1-C4 alkyl, hydroxyC1-C4 alkyl or C1-C4 alkoxy;

[0033] Z' is a monovalent functional group as shown in Formula 2,

[0034] [ka]

[0035] In this case, in the formula 2, n is an integer of 1 or 2;

[0036] each A is independently a functional group selected from hydroxy, C1-C4 alkyl, and hydroxyC1-C4 alkyl, wherein at least one A is C1-C4 alkyl;

[0037] L is hydrogen, C1-C4 alkyl, hydroxy or hydroxyC1-C4 alkyl.

[0038] As used herein, the term "solvate" refers to a molecular complex of a compound of the invention (or a pharma- ceutically acceptable salt thereof) with one or more solvent molecules. These include those known in the art or commonly used, e.g., water, ethanol, etc. The term "hydrate" refers to the complex where the solvent molecule is water.

[0039] As used herein, the term "salt" or "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable derivative of the disclosed compounds, where the parent compound is modified by converting any acid or base moieties present into its salt form.

[0040] In one embodiment, the FLT3 inhibitor is a compound selected from the group consisting of compounds of the following formula 3, stereoisomers, tautomers, and combinations thereof:

[0041] [ka]

[0042] In the above Chemical Formula 3,

[0043] E f is fluorine, chlorine, bromine or iodine,

[0044] Q o is hydroxy, halogen, C1-C4 alkyl, hydroxyC1-C4 alkyl or C1-C4 alkoxy;

[0045] s is an integer of 1 or 2;

[0046] A o is a functional group selected from hydroxy, C1-C4 alkyl, and hydroxyC1-C4 alkyl, and t is an integer of 1 or 2.

[0047] For example, the FLT3 inhibitor is a compound having FLT3 inhibitory activity described in Korean Patent Application No. 10-2018-0086768, and examples thereof include those shown in the following table. 1 The compound may be a compound selected from the group consisting of the compounds listed in items 1 to 32 of the above, or any pharma- ceutically acceptable salt or hydrate thereof.

[0048] [Table 1-1]

[0049] [Table 1-2]

[0050] [Table 1-3]

[0051] In one embodiment, the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, or a pharma- ceutically acceptable salt thereof, or a hydrate thereof.

[0052] In this specification, hypomethylating agents (HMA) refer to substances for hypomethylating DNA or DNA demethylating agents. DNA methylation is a major mechanism for regulating gene expression in cells, and increased DNA methylation blocks the activity of suppressor genes that regulate cell division and cell proliferation, leading to unregulated cell division and cancer progression. Hypomethylating agents can, for example, interfere with DNA methylation, restore tumor suppressor genes, regulate tumor proliferation, or interfere with cell metabolism by forming structures similar to substances necessary for tumor cell metabolism, thereby acting as antimetabolic agents that exhibit tumor proliferation suppressive effects.

[0053] In the present specification, the hypomethylating agent (HMA) is, for example, 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (ingredient name: azacitidine (azac itidine), 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one (chemical name: decitabine), or

[0054] These include, but are not limited to, hypomethylating agents (HMAs) in any pharma- ceutically acceptable salt or hydrate form thereof.

[0055] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, a pharma- ceutically acceptable salt thereof, or a hydrate thereof.

[0056] In one embodiment, the hypomethylating agent (HMA) is any one selected from 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, or a pharma- ceutically acceptable salt or hydrate thereof, and the FLT3 inhibitor is any one selected from the compound of Formula 1, its stereoisomers, and tautomers.

[0057] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one or 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, and the FLT3 inhibitor is any one selected from the compound of formula 3, its stereoisomers, and tautomers.

[0058] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one or 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one and the FLT3 inhibitor is also 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine.

[0059] In one embodiment, the composition includes an FLT3 inhibitor, or a pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or a pharma- ceutically acceptable salt or hydrate thereof, in which the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, and the FLT3 inhibitor is any one selected from the group consisting of the compound of Formula 1, its stereoisomers, and tautomers.

[0060] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, and the FLT3 inhibitor is any one selected from the compound of formula 3, its stereoisomers, and tautomers.

[0061] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine- 1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine.

[0062] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, and the FLT3 inhibitor is any one selected from the compound of formula 1, its stereoisomers, and tautomers.

[0063] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, and the FLT3 inhibitor is any one selected from the compound of formula 3, its stereoisomers, and tautomers.

[0064] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one and the FLT3 inhibitor is also 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine.

[0065] As an FLT3 inhibitor according to one embodiment, 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine inhibits kinases such as SYK, which are known to be associated with acute myeloid leukemia (AML) resistance. Among them, SYK kinase transcribes FLT3 through direct physical interaction, is important for the development of FLT3-ITD-induced myelodysplasia, and is primarily activated in FLT3-ITD-positive acute myeloid leukemia (AML). Therefore, activation of other signaling pathways of kinases such as SYK also causes resistance in the treatment of acute myeloid leukemia (AML) patients.

[0066] In one embodiment, the FLT3 inhibitor has excellent therapeutic effects against acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutation, which is associated with a high risk of relapse, poor prognosis, and reduced overall survival rate after treatment.

[0067] The FLT3 inhibitor according to one embodiment shows clinical benefits in acute myeloid leukemia (AML) patients who are resistant to conventional therapeutic agents. In about 30% of acute myeloid leukemia (AML) patients, activating mutations in the internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations of FLT3 are reported as oncogenic driver mutations. For example, the TKD mutations also include internal tandem duplications (ITDs).

[0068] In one embodiment, the acute myeloid leukemia (AML) to be treated using the pharmaceutical composition is also an acute myeloid leukemia (AML) with an FLT3 mutation.

[0069] The acute myeloid leukemia (AML) may also have a mutation in the tyrosine kinase domain (TKD) of the FLT3 amino acid sequence (FLT3-TKD). The FLT3-TKD mutation may also additionally include an internal tandem duplication (ITD). The FLT3-TKD mutation may include FLT3(D835Y), FLT3(F691L), FLT3(F691L / D835Y), FLT3(ITD / D835Y), FLT3(ITD / F69 1L), and combinations thereof.

[0070] According to one embodiment, a pharmaceutical composition comprising an FLT3 inhibitor, a pharma- ceutical acceptable salt thereof, or a solvate thereof, and a hypomethylating agent, a pharma- ceutical acceptable salt thereof, or a solvate thereof, administered in combination, has excellent therapeutic effects against acute myeloid leukemia (AML) having an FLT3 mutation.

[0071] In one embodiment, the acute myeloid leukemia (AML) is also a mutant FLT3 polynucleotide-positive acute myeloid leukemia (AML), an FLT3 internal tandem duplication (ITD)-positive acute myeloid leukemia (AML), or an acute myeloid leukemia (AML) with a FLT3 point mutation.

[0072] In one embodiment, the present invention relates to a pharmaceutical composition for treating acute myeloid leukemia (AML) comprising an FLT3 inhibitor, which is a compound of Formula 1, or a pharma- ceutical acceptable salt, or a solvate thereof, and the acute myeloid leukemia (AML) also has a mutation in the tyrosine kinase domain (TKD) of the FLT3 amino acid sequence (FLT3-TKD).

[0073] In one embodiment, the FLT3-TKD mutation additionally comprises an internal tandem duplication (ITD).

[0074] In one embodiment, the FLT3-TKD mutation includes any one selected from the group consisting of FLT3(D835Y), FLT3(F691L), FLT3(F691L / D835Y), FLT3(ITD / D835Y), FLT3(ITD / F691L), and combinations thereof.

[0075] In one embodiment, the FLT3 inhibitor is 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, or a pharma- ceutically acceptable salt or hydrate thereof.

[0076] A pharmaceutical composition according to one embodiment may comprise an FLT3 inhibitor for treating acute myeloid leukemia (AML) with FLT3 mutations, e.g., acute myeloid leukemia (AML) with internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) point mutations of FLT3, e.g., FLT3(ITD / D835Y) and FLT3(ITD / F691L), or any pharma- ceutically acceptable salt or hydrate thereof.

[0077] The FLT3-TKD mutation also includes one or more amino acid mutations in the region of positions 823 to 861 of the FLT3 amino acid sequence. The TKD mutation also includes at least one amino acid mutation selected from the group consisting of positions 835, 836, and 842 of the FLT3 amino acid sequence. For example, the TKD mutation also includes a mutation of the 835th amino acid of the FLT3 amino acid sequence. For example, the TKD mutation also includes a substitution of the 835th aspartic acid of the FLT3 amino acid sequence with valine, tyrosine, histidine, glutamic acid, or asparagine. For example, the TKD mutation also includes a substitution of the 836th isoleucine of the FLT3 amino acid sequence with leucine or aspartic acid. For example, the TKD mutation also includes a substitution of the 842nd tyrosine of the FLT3 amino acid sequence with cysteine ​​or histidine. For example, the mutation is FLT3(D835Y).

[0078] The FLT3-TKD mutation may have at least one amino acid mutation selected from the group consisting of amino acid 621, 627, 676, 691, and 697 of the FLT3 amino acid sequence. For example, the TKD mutation may be a substitution of phenylalanine at amino acid 691 with leucine in the FLT3 amino acid sequence. For example, the mutation may be FLT3(F691L).

[0079] The TKD mutation may also include an additional internal tandem duplication (ITD), for example, the mutation may be FLT3(ITD / D835Y) or FLT3(ITD / F691L).

[0080] In one specific example, 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, an FLT3 inhibitor, is tested for its ability to overcome resistance due to FLT3 mutations and for its therapeutic effect in in vivo studies using Ba / F3 cells expressed in xenograft mouse models of FLT3 ITD / F691L or FLT3 ITD / D835Y.

[0081] According to one embodiment, the FLT3 inhibitor shows an effect of overcoming resistance in acute myeloid leukemia (AML) treatment. For example, the FLT3 inhibitor shows suppressive activity against drug-resistant point mutations of FLT3 (D835Y, F691L or F691L / D835Y) caused by D835Y and F691L point mutations acquired by FLT3-TKD. In one embodiment, the TKD mutation is a substitution of aspartic acid at position 835 of the FLT3 amino acid sequence with tyrosine. In one embodiment, the mutation is FLT3(D835Y) or FLT3(ITD / D835Y). In one embodiment, the TKD mutation is a substitution of phenylalanine at position 691 of the FLT3 amino acid sequence with leucine. The mutation is FLT3(F691L) or FLT3(ITD / F691L).

[0082] According to one embodiment of the present invention, the FLT3 inhibitor was subjected to an in vitro site-directed competition binding assay using an acute myeloid leukemia (AML) resistant cell line, and the ability to overcome resistance caused by FLT3 mutation and the therapeutic effect were verified through a standard proliferation assay, immunoblotting, and apoptosis analysis.

[0083] The FLT3 inhibitor according to the embodiment strongly inhibits the mutations of FLT3(ITD / D835Y) and FLT3(ITD / F691L) in preclinical evaluation. The FLT3 inhibitor according to the embodiment exhibits high in vitro binding affinity in both of the two mutations, and exhibits strong inhibitory activity in vitro and in vivo using Ba / F3 cell lines expressing FLT3(ITD / D835Y) or FLT3(ITD / F691L). Furthermore, the FLT3 inhibitor according to the embodiment exhibits high cytotoxicity in MOLM-14 cell lines carrying FLT3 ITD, and can overcome FL-induced drug resistance. The FLT3 inhibitor according to the embodiment can strongly inhibit phosphorylation of SYK, STAT3, and STAT5 in KG-la cells.

[0084] In addition, the FLT3 inhibitor according to one embodiment of the present invention may be used in combination with one or more other leukemia treatment drugs, such as an inhibitor of apoptosis protein P (IAP) inhibitor or combination therapy, to exhibit a synergistic effect.

[0085] In one embodiment, the FLT3 inhibitor, or a pharma- ceutically acceptable salt or solvate thereof, is combined with a hypomethylating agent (HMA), or a pharma- ceutically acceptable salt or solvate thereof. The administration may be simultaneous, sequential, reversed or separate.

[0086] Exemplary routes of administration include, but are not limited to, oral, intravenous, intraarterial, intraperitoneal, intranasal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, and rectal administration.

[0087] The dosage form for administration in one embodiment may be formulated and used in any suitable form, including oral dosage forms such as tablets, powders, granules, capsules, suspensions, emulsions, syrups, and aerosols; topical preparations such as ointments and creams; injections; suppositories, and sterile injection solutions, by conventional methods.

[0088] As an FLT3 inhibitor according to one embodiment, 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, or any pharma- ceutically acceptable salt or hydrate thereof, may be administered orally.

[0089] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (chemical name: azacitidine), which is administered by intravenous, intraperitoneal or subcutaneous injection.

[0090] In one embodiment, the hypomethylating agent (HMA) is 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one (chemical name: decitabine), which is administered by intravenous, intraperitoneal or subcutaneous injection.

[0091] In one embodiment, the composition comprises a FLT3 inhibitor, or a pharma- ceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA), or a pharma- ceutically acceptable salt or solvate thereof, each in a therapeutically effective amount.

[0092] In one embodiment, the present invention includes an FLT3 inhibitor, a pharma- ceutically acceptable salt thereof, or a solvate thereof, and a hypomethylating agent (HMA), a pharma- ceutically acceptable salt thereof, or a solvate thereof, in therapeutically effective amounts for simultaneous, sequential, reversed or separate use as drugs for the treatment of acute myeloid leukemia (AML).

[0093] In one embodiment of the pharmaceutical composition, the FLT3 inhibitor is administered in an amount of 0.01 to 3,000 mg, for example, 0.1 to 1,000 mg or 6 to 600 mg. Alternatively, the FLT3 inhibitor is administered in an amount of 0.001 to 200 mg / kg body weight, for example, 0.05 to 100 mg / kg body weight, 0.1 to 50 mg / kg body weight, or 0.1 mg / kg to 10 mg / kg body weight. Alternatively, the FLT3 inhibitor is administered in an amount of 0.001 to 200 mg / kg body weight / daily dose, for example, 0.05 to 50 mg / kg body weight / daily dose or 0.1 mg / kg to 10 mg / kg body weight / daily dose. Alternatively, the FLT3 inhibitor is administered in an amount of 0.01 mg / m 2 or 1,000 mg / m 2 of body surface area, e.g., 3.7 mg / m 2 or 370 mg / m 2 It is also administered in an amount of 0.1 mg / kg body surface area.

[0094] In one embodiment of the pharmaceutical composition, the hypomethylating agent (HMA) is administered in an amount of 0.1 to 2,000 mg, such as 1 to 1,500 mg, 20 mg to 500 mg, or 1 mg to 150 mg. Alternatively, the hypomethylating agent (HMA) is administered in an amount of 0.001 to 400 mg / kg body weight, such as 0.001 to 100 mg / kg body weight, or 0.2 mg / kg to 200 mg / kg body weight. Alternatively, the hypomethylating agent (HMA) may be administered in an amount of 0.01 to 300 mg / kg body weight / daily dose, for example, 0.2 mg to 200 mg / kg body weight / daily dose, or 0.017 mg to 2.5 mg / kg body weight / daily dose. Alternatively, the hypomethylating agent (HMA) may be administered in an amount of 0.01 mg / m 2 or 1,000 mg / m 2 of body surface area, e.g., 6 mg / m 2 or 92.5 mg / m 2 , or 7.4 mg / m 2 or 740 mg / m 2 It is also administered in an amount of 0.1 mg / kg body surface area.

[0095] The amount of the two combined drugs to be administered to a patient can be determined by the attending diagnostician, who is skilled in the art, by using known techniques and observing the results obtained under similar circumstances. In determining the effective amount or dose of the compound to be administered, numerous factors are taken into consideration by the attending diagnostician, including, but not limited to, the species of mammal; its size, age, and general health; the specific neoplasm involved; the extent, association, or severity of the neoplasm; the response of the individual patient; the specific compound to be administered; the mode of administration; the bioavailability characteristics of the formulation to be administered; the selected dosage; the use of concomitant drugs; and other relevant circumstances. For example, when administered orally, the daily dose is about 0.001 to about 100 mg / kg, e.g., about 0.005 to about 30 mg / kg, e.g., about 0.01 to about 10 mg / kg, of the patient's body weight. When administered intravenously, the daily dose is suitably about 0.0001 to about 10 mg / kg of the patient's body weight, the total being administered in one or more divided doses throughout the day. Mucosal formulations are administered at a dose of about 0.001 to about 100 mg / kg of body weight, either once a day or in divided doses per day. For example, azacitidine is administered in an amount of about 250 to about 500 mg per day.

[0096] As a specific example of a hypomethylating agent (HMA), 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (active ingredient: azacytidine, trade name: Vidaza) is administered to a patient with a body surface area of ​​1 m 2 Approximately 5 mg per m of patient body surface area 2 A dose of about 125 mg per m 2 to about 100 mg / m 2 , for example, about 75 mg / m 2 The recommended starting dose for the first treatment cycle is 75 mg / m2 Vidaza daily for 7 days for all patients, regardless of baseline hematological values. 2 is administered by subcutaneous (SC) injection or intravenous (IV) infusion. Patients may be premedicated for nausea and vomiting. Treatment cycles may be repeated every 4 weeks. After two cycles, if no beneficial effect is seen and no toxicities other than nausea and vomiting occur, the dose may be increased to 100 mg / m2. で The dose can be increased. Patients must be treated for a minimum of 4 to 6 cycles. A complete or partial response requires additional cycles of treatment.

[0097] The dosage of a pharmaceutical composition according to an embodiment, or the dosage or therapeutically effective amount of the FLT3 inhibitor and hypomethylating agent (HMA) in said composition, varies within wide tolerances and is determined as known in the art. The dosage is adjusted to suit the individual requirements of each particular case, including the patient being treated, the specific compound being administered, the route of administration (oral, parenteral), and the condition being treated.

[0098] The daily dosage can be administered in single or divided doses, or for parenteral administration, it can be given by continuous infusion.

[0099] In one embodiment of the pharmaceutical composition, the FLT3 inhibitor and the hypomethylating agent (HMA) are administered simultaneously, sequentially, or separately without any specific time limit. Here, such administration is meant to provide a therapeutically effective level of the two compounds in the patient's body. The interval between administrations can be seconds, minutes, hours, or days at a given interval, and can have a pause if necessary.

[0100] The term "composition" or "pharmaceutical composition" as used herein means a mixture containing a compound disclosed herein and at least one, and optionally more than one, other pharma- ceutically acceptable chemical component, e.g., a pharma- ceutically acceptable excipient.

[0101] The pharmaceutical composition may further include one or more pharma- ceutically acceptable additives selected from the group consisting of excipients, binders, disintegrants, lubricants, and any combination thereof. The additives may be any substances known to those skilled in the art to be useful in the manufacture of dosage forms, and may be adjusted as necessary, for example, according to the mode of administration of the drug.

[0102] Another aspect of the present invention provides a pharmaceutical kit in which the pharmaceutical compositions are administered simultaneously, sequentially, in reverse order or separately.

[0103] Another aspect of the present invention provides a pharmaceutical composition for treating acute myeloid leukemia (AML), comprising a hypomethylating agent (HMA), or a pharma- ceutical acceptable salt or solvate thereof, in combination with an Fms-like tyrosine kinase (FLT3) inhibitor, or a pharma- ceutical acceptable salt or solvate thereof.

[0104] In one embodiment, the FLT3 inhibitor is a compound selected from the group consisting of the compounds of formula 1, stereoisomers, tautomers, and combinations thereof.

[0105] In another embodiment, the FLT3 inhibitor is a compound selected from the compound of formula 3, its stereoisomers, tautomers, and combinations thereof.

[0106] Another aspect of the present invention is a method for treating a rheumatoid arthritis, comprising administering to a patient a therapeutically effective amount of at least one active ingredient selected from the group consisting of: (a) an Fms-like tyrosine kinase (FLT3) inhibitor, or any pharma-ceutically acceptable salt or hydrate thereof; and (b) a hypomethylating agent (HMA), or any pharma-ceutically acceptable salt or hydrate thereof,

[0107] The active ingredients are administered simultaneously, sequentially, in reverse order or separately to provide a pharmaceutical combination for the treatment of acute myeloid leukemia (AML).

[0108] Another aspect of the present invention provides a method for treating acute myeloid leukemia (AML), comprising administering, simultaneously, sequentially, in reverse order or separately, the following active ingredients:

[0109] (a) a therapeutically effective amount of an Fms-like tyrosine kinase (FLT3) inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and

[0110] (b) A hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof.

[0111] Another aspect of the present invention provides a method of treating acute myeloid leukemia (AML) in a patient, comprising administering, simultaneously, sequentially, in reverse order or separately, the following active ingredients:

[0112] (a) said patient is administered a therapeutically effective amount of an Fms-like tyrosine kinase (FLT3) inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof; and

[0113] (b) said patient is administered a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof.

[0114] In one embodiment, at least one of said step (a) and said step (b) is also under the direction or control of a physician.

[0115] Another aspect of the present invention provides a method of treating acute myeloid leukemia (AML) in a patient, the method comprising the steps of:

[0116] (a) prescribing to a patient for self-administration a therapeutically effective amount of an Fms-like tyrosine kinase (FLT3) inhibitor, or any pharma- ceutical acceptable salt or hydrate thereof; and

[0117] (b) administering to the patient a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof.

[0118] In one embodiment, a pharmaceutical combination for treating acute myeloid leukemia (AML) is provided, comprising as active ingredients an Fms-like tyrosine kinase (FLT3) inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof, wherein the two active ingredients are administered simultaneously, sequentially or separately.

[0119] In one embodiment, a pharmaceutical combination is provided that includes an FLT3 inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof. In one embodiment, the combination includes the FLT3 inhibitor and the hypomethylating agent (HMA) in the form of a salt or hydrate formed from the two components. For example, the salt is formed partially or completely.

[0120] In one embodiment, a method for treating a subject suffering from acute myeloid leukemia (AML) using a composition comprising an FLT3 inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof, as active ingredients is provided. In this case, the two active ingredients may be administered simultaneously, sequentially, in reverse order, or separately. In one embodiment, a method for treating acute myeloid leukemia (AML) with FLT3 mutation is provided using the composition.

[0121] In one embodiment, the acute myeloid leukemia (AML) includes mutant FLT3 polynucleotide-positive acute myeloid leukemia (AML), FLT3 internal tandem duplication (ITD)-positive acute myeloid leukemia (AML), or acute myeloid leukemia (AML) with a FLT3 point mutation.

[0122] Another aspect of the present invention provides the use of a combination comprising, as active ingredients, an FLT3 inhibitor, or any pharma- ceutically acceptable salt or hydrate thereof, and a hypomethylating agent (HMA), or any pharma- ceutically acceptable salt or hydrate thereof, for use in the manufacture of a medicament for treating acute myeloid leukemia (AML).

[0123] Combination therapy of an FLT3 inhibitor and a hypomethylating agent (HMA) using a combination according to one embodiment of the present invention has an improved therapeutic effect compared to the effect of administering the FLT3 inhibitor or the hypomethylating agent (HMA) alone. The therapeutic effect using the combination according to one embodiment shows a synergistic therapeutic effect that is greater than or equal to the arithmetic sum of two or more drugs used in combination.

[0124] As used herein, the term "therapeutically effective amount" refers to a combination of A therapeutically effective amount is an amount of a compound that treats acute myeloid leukemia (AML) when administered in a dose that is proven to be a therapeutically effective amount for a particular subject at a given moment, even if the clinician considers such a dose to be a therapeutically effective amount, it will not be effective for 100% of similarly treated subjects for that disease. The amount of a compound that corresponds to a therapeutically effective amount also depends on the specific type of cancer, the stage of the cancer, the age of the patient being treated, and other factors. In general, therapeutically effective amounts of such compounds are well known in the art.

[0125] A therapeutically effective amount may also be a combination amount in which one or both of the FLT3 inhibitor or hypomethylating agent (HMA) are administered in a sub-therapeutically effective amount or dose to treat acute myeloid leukemia (AML). A sub-therapeutically effective amount is an amount of compound that, when administered alone to a patient, does not completely inhibit the biological activity of the intended target over time.

[0126] One aspect of the present invention includes the administration of the combination or its use according to a therapeutically effective interval. The therapeutically effective interval is the time period that begins when one of the compounds is administered to a patient and ends at the limit of administration of the other compound at which the benefits of the combined administration of the two compounds are maintained. Thus, the combined administration can be simultaneous or sequential or in any order.

[0127] The time period or cycle of combined administration can be one week, 28 days, one month, two months, three months or four months or more.Each drug can be administered every day for the entire duration of each period or cycle, or only for a part of it.For example, in a 28-day cycle, FLT3 inhibitor or any pharmaceutically acceptable salt or hydrate thereof can be administered every day in the cycle, while hypomethylating agent (HMA) or any pharmaceutically acceptable salt or hydrate thereof can be administered for a part of it, such as for 5 consecutive days, 7 consecutive days or 10 consecutive days, and 5 consecutive days, 7 consecutive days and 10 consecutive days are also the first 5 days, 7 days or 10 days of each period or cycle.

[0128] The term "combination" or "pharmaceutical combination" as used herein means a product produced from the mixing or combination of two or more active ingredients, including both fixed and non-fixed combinations of active ingredients. The term "fixed combination" means that the active ingredients, for example, the compounds disclosed herein, and one or more additional therapeutic agents are administered to a subject at the same time in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, for example, the compounds disclosed herein, and one or more additional therapeutic agents are administered to a subject as separate entities, either simultaneously, simultaneously or sequentially, without any specific time limit, where such administration provides a therapeutically effective level of the active ingredients in the subject's body. The latter also applies to cocktail therapy, for example, administration of three or more active ingredients.

[0129] The term "subject" as used herein includes mammals, including humans, and non-mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, mice, guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc.

[0130] As used herein, the terms "treating," "treat," "is intended to treat," or "treatment" include limiting, slowing, halting, reducing or reversing the progression or severity of an existing symptom, disease, condition, or disorder.

[0131] The term "up to" used in this specification refers to a range including the numerical values ​​before and after the term "up to" as the lower and upper limits, respectively. It means an interval between the numerical values ​​including the numerical values ​​before and after the term "up to." The numerical values ​​may also be a range in which any number of the upper and / or lower limits is selected and combined.

[0132] In the present specification, the industrial applicability is exemplified by the utility of the present combination therapy being demonstrated by a positive impact in one or more of the aforementioned studies involving the description of one or more parameters.

[0133] The present invention will be described in more detail below with reference to the following examples and experimental examples. However, these examples and experimental examples are intended to aid in the understanding of the present invention and are not intended to limit the scope of the present invention in any way. EXAMPLES

[0134] [Example 1]

[0135] Evaluation of cell growth inhibitory activity in combination with azacitidine

[0136] The effect of the combination of drugs was examined through the growth inhibition of MOLM-13 (DSMZ no. ACC 554) cells treated with the FLT3 inhibitor 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine (hereinafter referred to as Compound A) and the hypomethylating agent (HMA) 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (hereinafter referred to as azacytidine). MOLM-13 cells were cultured in RPMI 1640 medium (RPMI: Rosewell Parker Memory Institute) containing 20% ​​FBS at 2 x 10 cells per well. 4 The same culture medium was used to inoculate the compound A to a set concentration (e.g., 10 to 0.078 nM) in a 1 / 2 stepwise dilution. In the case of azacytidine, the concentration (GI) that inhibited MOLM-13 cell growth by about 40% was used. 40 The cells were diluted with culture medium to 800 nM, and then treated with Compound A or alone and cultured for 3 days. The viability of the cells was measured by CTG (CellTiter-Glo®) test, and the 50% inhibition value (GI) of cell growth was used for the analysis of the results.50 ) was calculated using GraphPad Prism software. The results are shown in Table 2 , and shown in Figs. 1 and 2.

[0137] See table below 2 1 shows data on the growth inhibitory activity of compound A alone or in combination with other compounds in MOLM-13 cells.

[0138] [Table 2]

[0139] 1 shows the degree of inhibition of MOLM-13 cell growth by combined treatment with Compound A and azacytidine. The Y axis shows the cell growth rate (%), and the X axis shows the logarithmic concentration of Compound A (log value of nM unit concentration).

[0140] FIG. 2 shows the degree of cell growth inhibition when compound A 2.5 nM, azacytidine 800 nM, or a combination of compound A 2.5 nM and azacytidine 800 nM was used, in which the Y axis indicates the cell growth rate (%) and the X axis indicates each experimental group.

[0141] As a result, as can be seen from Table 2 and Figures 1 and 2, the cell growth inhibitory effect was superior in the group administered with compound A in combination with azacitidine compared to the group administered with compound A or azacitidine alone.

[0142] [Example 2]

[0143] Mouse model xenografted with MOLM-13-Luc2 cell line

[0144] A comparative or combined efficacy test of Compound A and Azacitidine was conducted in a mouse model xenografted with MOLM-13-Luc2 cell line, a MOLM-13 cell line genetically modified to express luciferase.

[0145] MOLM-13-Luc2 cell line was cultured at 5 × 10 6 The cells were inoculated into the tail vein of NOG mice at 0.1 mL / mouse and allowed to grow.

[0146] Bioluminescence images of MOLM-13-Luc2 cells were taken with Lumina III. The images were measured using an IVIS imaging system (PerkinElmer) and quantified using Living Image software (PerkinElmer). During the measurement, mice were intraperitoneally injected with D-luciferin and imaged under anesthesia using isoflurane. The images were measured for the first group separation during the experiment, and then on specific days depending on the test purpose.

[0147] The control group was orally administered a DMSO / PEG400 / DW (ratio = 0.5 / 2 / 7.5, v / v) mixed solution once a day, the compound A group was orally administered 10 mg / kg / day once a day, and the hypomethylating agent (HMA) administered group, azacitidine group, was intraperitoneally administered 3 mg / kg / day twice a week (days 1 and 4 of each week). In the combination group, compound A was orally administered 10 mg / kg / day once a day, and azacitidine was intraperitoneally administered 3 mg / kg / day twice a week (days 1 and 4 of each week). Each group was administered an individual drug until all individuals in each group died.

[0148] The experimental results are shown in Figure 3. Figure 3 shows the antitumor effect of administering a combination of Compound A (FLT3 inhibitor) and hypomethylating agent (HMA) to nude mice xenografted with MOLM-13-Luc2 cell line. The Y axis shows the percentage (survival rate) (%) of surviving mice in each experimental group, and the X axis shows the number of days of administration.

[0149] As shown in Figure 3, the antitumor effect of drug administration was confirmed by measuring survival time, and the median survival time and overall survival time in the combination group were found to be 30 days and 31 days, respectively. Also, as shown in Figure 3, the results were longer than the median survival time (16 days) and overall survival time (18 days) in the azacitidine group, which is a hypomethylating agent (HMA) administration group, and were longer than the median survival time (17 days) and overall survival time (20 days) in the compound A administration group.

[0150] In addition, the experimental results using the mouse efficacy model orthotopically transplanted with MOLM-13-Luc2 shown in Figure 3 showed that the survival period was extended and the antitumor efficacy was superior in the group administered the FLT3 inhibitor and hypomethylating agent (HMA) in combination, compared to the group administered only the FLT3 inhibitor compound A (compound A alone group) or the group administered only the hypomethylating agent (HMA) (azacytidine alone group).

[0151] In addition, the above results indicate that the combination of the FLT3 inhibitor 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine with the hypomethylating agent (HMA) 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one (azacytidine) improved antitumor activity. It is known to be effective.

[0152] The present invention has been described above with reference to its specific examples. Those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the present invention. Therefore, the disclosed specific examples should be considered from an illustrative rather than a restrictive perspective. The scope of the present invention is defined in the claims, not the above description, and all differences within the scope of the equivalents thereto should be interpreted as being included in the present invention.

Claims

1. A compound of the following chemical formula 1, a stereoisomer thereof, a tautomer thereof, a combination thereof, or a pharma- ceutically acceptable salt or solvate thereof: Hypomethylating agents (HMAs), pharma- ceutically acceptable salts, or solvates thereof; A pharmaceutical combination comprising: [Formula 1] In the above Chemical Formula 1, E a is hydrogen, hydroxy or C 1 -C 4 is an alkoxy; E b is hydrogen, halogen, C 1 -C 4 Alkyl or C 1 -C 4 is a fluoroalkyl; E c and E. d are, independently of each other, hydrogen or hydroxy, X' is hydrogen or hydroxy; k is an integer of 1 or 2; Each Q is independently hydroxy, halogen, C 1 -C 4 Alkyl, Hydroxy C 1 -C 4 Alkyl or C 1 -C 4 is an alkoxy; Z′ is a monovalent functional group as shown in Formula 2, [Case 2] In this case, in Formula 2, n is an integer of 1 or 2; Each A is independently hydroxy, C 1 -C 4 Alkyl and Hydroxy C 1 -C 4 alkyl, wherein at least one A is selected from the group consisting of C 1 -C 4 is alkyl, L is hydrogen, C 1 -C 4 Alkyl, hydroxy or hydroxy C 1 -C 4 It is an alkyl.

2. The combination drug according to claim 1, wherein the compound of formula 1 is a compound selected from the group consisting of compounds of formula 3, stereoisomers thereof, tautomers thereof, and combinations thereof: [C3] In the above Chemical Formula 3, E f is fluorine, chlorine, bromine or iodine, Q o is hydroxy, halogen, C 1 -C 4 Alkyl, Hydroxy C 1 -C 4 Alkyl or C 1 -C 4 is an alkoxy; s is an integer of 1 or 2; A o is hydroxy, C 1 -C 4 Alkyl and Hydroxy C 1 -C 4 alkyl; and t is an integer of 1 or 2.

3. The compound of formula 3 is 5-chloro-N-(3-cyclopropyl-5-(((3R, 3. The pharmaceutical combination according to claim 2, which is 5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, a pharma- ceutically acceptable salt thereof, a stereoisomer thereof, or a hydrate thereof.

4. The combination pharmaceutical according to any one of claims 1 to 3, wherein the hypomethylating agent (HMA) is any one selected from the group consisting of 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one, and pharma- ceutical acceptable salts thereof, or hydrates thereof.

5. The pharmaceutical combination of claim 4, wherein the HMA is 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one.

6. The pharmaceutical combination of claim 4, wherein the HMA is 4-amino-1-((2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one.

7. The combination pharmaceutical according to claim 1, wherein the compound of formula 1 is a compound selected from the group consisting of the following compounds: 1) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-amine 2) 5-chloro-4-(6-chloro-1H-indol-3-yl)-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-amine 3) 2-((2R,6S)-4-(3-((5-chloro-4-(6-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol 4) 2-((2R,6S)-4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-yl)ethan-1-ol 5) 2-((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)- 2,6-Dimethylpiperazin-1-yl)ethan-1-ol 6) (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine 7) (R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 8) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 9) 5-chloro-N-(3-cyclopropyl-5-(((3S,5R)-3-ethyl-5-methylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 10) 5-chloro-N-(3-cyclopropyl-5-((3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pi Rimidin-2-amine 11) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 12) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-fluoro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 13) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(1H-indol-3-yl)-5-methylpyrimidin-2-amine 14) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-5-methyl-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 15) N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-amine 16) (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-6-yl)methanol 17) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(5-methoxy-6-methyl-1H-indol-3-yl)pyrimidin-2-amine 18) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methyl-1H-indol-5-ol 19) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methylindolin-2-one 20) 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-methoxy-6-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 21) 5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)amino)-6-(6-methyl-1H-indol-3-yl)pyrimidin-4-ol 22) 3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3, 5-Dimethylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)-6-methyl-1H-indol-7-ol 23) 2-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol 24) 4-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-cyclopropyl-6-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenol 26) ((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-6-methylpiperazin-2-yl)methanol 28) 5-chloro-N-(3-cyclopropyl-5-(((3R,5R)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 29) 5-chloro-N-(3-cyclopropyl-5-(((3S,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 31) (2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-cyclopropylbenzyl)-2,6-dimethylpiperazin-1-ol 32) (2R,6S)-4-(3-cyclopropyl-5-((4-(6-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)benzyl)-2,6-dimethylpiperazin-1-ol.

8. A pharmaceutical composition comprising the combination drug according to any one of claims 1 to 7.

9. A combination pharmaceutical according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 for treating acute myeloid leukemia (AML).

10. The pharmaceutical combination or pharmaceutical composition according to claim 9, wherein the AML is AML with a FLT3 mutation.

11. 10. The pharmaceutical combination or pharmaceutical composition of claim 9, wherein the AML is mutant FLT3 polynucleotide-positive AML, FLT3 internal tandem duplication (ITD)-positive AML, or AML with a FLT3 point mutation.

12. The combination pharmaceutical or pharmaceutical composition according to claim 9, wherein the AML has a mutation in the tyrosine kinase domain of the FLT3 amino acid sequence (FLT3-TKD).

13. The pharmaceutical combination or pharmaceutical composition of claim 12, wherein the FLT3-TKD mutation further comprises an internal tandem duplication (ITD).

14. 13. The pharmaceutical combination or pharmaceutical composition of claim 12, wherein the FLT3-TKD mutation comprises a mutation selected from the group consisting of FLT3(D835Y), FLT3(F691L), FLT3(F691L / D835Y), FLT3(ITD / D835Y), FLT3(ITD / F691L), and combinations thereof.

15. The combination drug or pharmaceutical composition according to any one of claims 9 to 14, comprising a therapeutically effective amount of each of the compound of formula 1, or a pharma- ceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA), or a pharma- ceutically acceptable salt or solvate thereof.

16. The combination pharmaceutical or pharmaceutical composition according to any one of claims 9 to 15, wherein the compound of formula 1, or a pharma- ceutically acceptable salt or solvate thereof, is administered simultaneously, sequentially, in reverse order, or separately with the HMA, or a pharma- ceutically acceptable salt or solvate thereof.

17. The pharmaceutical combination or pharmaceutical composition according to any one of claims 9 to 16, wherein the compound of formula 1 and the hypomethylating agent (HMA) are formulated in a single dose or in a divided dose form.

18. A method for preparing a therapeutic agent for treating acute myeloid leukemia (AML) having one or more FLT3 mutations, comprising using a combination pharmaceutical comprising a compound of the following formula 1, a stereoisomer thereof, a tautomer thereof, a combination thereof, or a pharma- ceutical acceptable salt or solvate thereof: [C4] In the above Chemical Formula 1, E a is hydrogen, hydroxy or C 1 -C 4 is an alkoxy; E b is hydrogen, halogen, C 1 -C 4 Alkyl or C 1 -C 4 is a fluoroalkyl; E c and E. d are, independently of each other, hydrogen or hydroxy, X' is hydrogen or hydroxy; k is an integer of 1 or 2; Each Q is independently hydroxy, halogen, C 1 -C 4 Alkyl, Hydroxy C 1 -C 4 Alkyl or C 1 -C 4 is an alkoxy; Z′ is a monovalent functional group as shown in Formula 2, [C5] In this case, in Formula 2, n is an integer of 1 or 2; Each A is independently hydroxy, C 1 -C 4 Alkyl and Hydroxy C 1-C 4 alkyl, wherein at least one A is selected from the group consisting of C 1 -C 4 is alkyl, L is hydrogen, C 1 -C 4 Alkyl, hydroxy or hydroxy C 1 -C 4 It is an alkyl.

19. 19. The method of claim 18, wherein the compound of formula 1 is a compound selected from the group consisting of compounds of formula 3, stereoisomers thereof, tautomers thereof, and combinations thereof: [C3] In the above Chemical Formula 3, E f is fluorine, chlorine, bromine or iodine, Q o is hydroxy, halogen, C 1 -C 4 Alkyl, Hydroxy C 1 -C 4 Alkyl or C 1 -C 4 is an alkoxy; s is an integer of 1 or 2; A o is hydroxy, C 1 -C 4 Alkyl and Hydroxy C 1 -C 4 alkyl; and t is an integer of 1 or 2.

20. 20. The method of claim 19, wherein the compound of formula 3 is 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine, a pharma- ceutically acceptable salt thereof, a stereoisomer thereof, or a hydrate thereof.

21. The method of any one of claims 18 to 20, wherein the AML is mutant FLT3 polynucleotide-positive AML, FLT3 internal tandem duplication (ITD)-positive AML, or AML with a FLT3 point mutation.

22. The method according to any one of claims 18 to 20, wherein the AML has a mutation in the tyrosine kinase domain of the FLT3 amino acid sequence (FLT3-TKD).

23. 23. The method of claim 22, wherein the FLT3-TKD mutation further comprises an internal tandem duplication (ITD).

24. 23. The method of claim 22, wherein the FLT3-TKD mutation is a mutation selected from the group consisting of FLT3(D835Y), FLT3(F691L), FLT3(F691L / D835Y), FLT3(ITD / D835Y), FLT3(ITD / F691L), and combinations thereof.

25. The AML is i) mutations in the tyrosine kinase domain (FLT3-TKD) and internal tandem duplications (ITDs) of the FLT3 amino acid sequence; ii) a mutation in the tyrosine kinase domain of the FLT3 amino acid sequence (FLT3-TKD) selected from FLT3(F691L) and FLT3(F691L / D835Y); or iii) mutations at amino acids 621, 627, 676, 691, 697, 836 and / or 842 of the FLT3 amino acid sequence; The method according to any one of claims 18 to 20, comprising:

26. 26. The method of claim 25, wherein the AML has a mutation in FLT3(ITD / D835Y) or FLT3(ITD / F691L).

Citation Information

Patent Citations

  • JPP6806931B

  • Combination of IAP inhibitors and FLT3 inhibitors

    KR1020090087094A

  • Combination therapy for the treatment of acute myeloid leukemia

    KR1020180124055A

  • Combination therapy for the treatment of acute myeloid leukemia

    WO2017170348A1

  • Pyrimidine compound and pharmaceutical use thereof

    WO2018139903A1